On January 2, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported that the company and its subsidiaries will present at upcoming investor conferences in San Francisco (Press release, Intrexon, JAN 2, 2019, View Source [SID1234532340]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pieter Rottiers, PhD, Chief Executive Officer of ActoBio Therapeutics, will present at the Biotech Showcase on January 8th, 2019 at 9:00 AM PT at the Hilton San Francisco Union Square.

Thomas D. Reed, PhD, Chief Science Officer of Intrexon and Amit Patel, MD, Founder of Xogenex, will present at the Biotech Showcase on January 9th, 2019 at 8:45 AM PT at the Hilton San Francisco Union Square.

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9th, 2019 at 11:30 AM PT at the Westin St. Francis Hotel. A live webcast of the presentation will be available on the Investors section of Intrexon’s website at View Source, and a replay of the webcast will be available for 30 days following the event.

Additionally, as previously announced, Helen Sabzevari, PhD, President of Precigen, will be presenting a first-look at Precigen’s preclinical and clinical portfolio at an investor event Monday, January 7, 2019 at 3:00pm PT. The presentation will be available via live audio webcast through Intrexon’s website at View Source. Spaces are available for individuals who would like to participate in-person at the onsite event. For in-person participation, RSVP is required, and all RSVPs must be received at [email protected] by January 6, 2019 at 5:00 pm PT.

On January 2, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, reported that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 7, 2019 at 4:30 p.m. PST (7:30 p.m. EST) (Press release, Merck & Co, JAN 2, 2019, View Source [SID1234532339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source

On January 2, 2019 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, reported that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 4:00 PM PT (7:00 PM ET) in San Francisco (Press release, Jounce Therapeutics, JAN 2, 2019, View Source;p=RssLanding&cat=news&id=2381812 [SID1234532338]). Following the presentation, management will participate in a question and answer session at 4:30 PM PT (7:30 PM ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.

On January 2, 2019 BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) reported that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 1:30 p.m. ET (Press release, BioCryst Pharmaceuticals, JAN 2, 2019, View Source [SID1234532337]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of these presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

On January 2, 2019 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Mark Enyedy, President and CEO, reported that it will present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Press release, ImmunoGen, JAN 2, 2019, View Source [SID1234532336]). The presentation is scheduled for 8:30am PT (11:30am ET) on January 9, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:00am PT (12:00pm ET).

A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.